Cargando…

Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol

Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia (CLL) treated with the cyclin dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46%...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blum, Kristie A., Ruppert, Amy S., Woyach, Jennifer A., Jones, Jeffrey A., Andritsos, Leslie, Flynn, Joseph M., Rovin, Brad, Villalona-Calero, Miguel, Ji, Jia, Phelps, Mitchell, Johnson, Amy J., Grever, Michael R., Byrd, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162125/ https://www.ncbi.nlm.nih.gov/pubmed/21606960 http://dx.doi.org/10.1038/leu.2011.109

Ejemplares similares

Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition
por: Ni, Wenjun, et al.
Publicado: (2010)

Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center
por: Stephens, Deborah M., et al.
Publicado: (2014)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
por: Heerema, Nyla A., et al.
Publicado: (2020)

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia
por: Flynn, Joseph, et al.
Publicado: (2015)

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia
por: Guinn, Daphne, et al.
Publicado: (2017)

The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells
por: Zocchi, Loredana, et al.
Publicado: (2018)

Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer
por: Hassan, Md Sazzad, et al.
Publicado: (2021)

Effect of P-glycoprotein on flavopiridol sensitivity
por: Boerner, S A, et al.
Publicado: (2001)

Flavopiridol Mitigates the Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Targeting Cyclin-Dependent Kinase 9
por: Jia, Qi, et al.
Publicado: (2022)

Antitumor effects of flavopiridol, a cyclin-dependent kinase inhibitor, on human cholangiocarcinoma in vitro and in an in vivo xenograft model
por: Saisomboon, Saowaluk, et al.
Publicado: (2019)

Potent interaction of flavopiridol with MRP1
por: Hooijberg, J H, et al.
Publicado: (1999)

The Pharmacological Implications of Flavopiridol: An Updated Overview
por: Joshi, Hemant, et al.
Publicado: (2023)

Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma
por: Zhang, Xu Hannah, et al.
Publicado: (2021)

Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia
por: Cohen, Jonathon B., et al.
Publicado: (2012)

Transgenic models are predictive: the herceptin and flavopiridol experience
por: Schmidt, E
Publicado: (2003)

Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
por: Chen, Timothy L., et al.
Publicado: (2016)

Complex effects of flavopiridol on the expression of primary response genes
por: Keskin, Havva, et al.
Publicado: (2012)

Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease
por: Hertlein, Erin, et al.
Publicado: (2013)

Mitochondrial Priming of Chronic Lymphocytic Leukemia Patients Associates Bcl-x(L) Dependence with Alvocidib Response
por: Pierceall, William E., et al.
Publicado: (2014)

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia
por: Yeh, Yuh-Ying, et al.
Publicado: (2014)

The angiogenic properties of Kaposi's sarcoma-associated herpesvirus encoded G-protein coupled receptor are reduced by flavopiridol, an inhibitor of cyclin-dependent kinase 9
por: McFerrin, Harris, et al.
Publicado: (2010)

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol
por: Lam, Lloyd T, et al.
Publicado: (2001)

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
por: Bond, David A, et al.
Publicado: (2020)

Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation
por: Hu, Zi’ang, et al.
Publicado: (2018)

Advanced Practice Perspectives on Preventing and Managing Tumor Lysis Syndrome and Neutropenia in Chronic Lymphocytic Leukemia
por: Goodrich, Amy
Publicado: (2021)

Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen
por: Cimica, Velasco, et al.
Publicado: (2010)

The radiation-sensitizing effect of flavopiridol in the esophageal cancer cell line Eca109
por: YAO, YUAN, et al.
Publicado: (2013)

Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
por: Li, Xiaoran, et al.
Publicado: (2017)

A Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma
por: Morris, Don G., et al.
Publicado: (2006)

Differential effects on HIV replication and T cell activation following direct inhibition of CDK9 or flavopiridol (FVP) treatment in primary peripheral blood lymphocytes
por: Salerno, D, et al.
Publicado: (2006)

Management of relapsed/refractory Chronic Lymphocytic Leukemia
por: Woyach, Jennifer A.
Publicado: (2022)

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2018)

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
por: Guinn, Daphne, et al.
Publicado: (2014)

Targeted Drug Delivery through Optical Control of Cell Lysis
por: Darrah, Kristie, et al.
Publicado: (2020)

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for 30-Day Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma
por: Jaglowski, Samantha M., et al.
Publicado: (2014)

Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response
por: Nilubol, Naris, et al.
Publicado: (2018)

Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models
por: Pinto, Nicole, et al.
Publicado: (2020)

HTLV-1 gene expression by individual infected clones determines susceptibility to lysis by cytotoxic T lymphocytes specific for Tax and HBZ
por: Rowan, Aileen G, et al.
Publicado: (2014)

A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Woyach, Jennifer A, et al.
Publicado: (2009)

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n8oiiaerkqog670jemb7a2u6jr